{"doi":"10.3390/ijms222112041","title":"Heparin and Derivatives for Advanced Cell Therapies","abstract":"<jats:p>Heparin and its derivatives are saving thousands of human lives annually, by successfully preventing and treating thromboembolic events. Although the mode of action during anticoagulation is well studied, their influence on cell behavior is not fully understood as is the risk of bleeding and other side effects. New applications in regenerative medicine have evolved supporting production of cell-based therapeutics or as a substrate for creating functionalized matrices in biotechnology. The currently resurgent interest in heparins is related to the expected combined anti-inflammatory, anti-thrombotic and anti-viral action against COVID-19. Based on a concise summary of key biochemical and clinical data, this review summarizes the impact for manufacturing and application of cell therapeutics and highlights the need for discriminating the different heparins.</jats:p>","journal":"International Journal of Molecular Sciences","year":2021,"id":648217,"datarank":0.6321740574531927,"base_score":3.044522437723423,"endowment":3.044522437723423,"self_citation_contribution":0.4566783656585135,"citation_network_contribution":0.1754956917946791,"self_endowment_contribution":0.4566783656585135,"citer_contribution":0.1754956917946791,"corpus_percentile":null,"corpus_rank":null,"citation_count":20,"citer_count":17,"citers_with_citation_signal":12,"citers_with_endowment":12,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1689138,"name":"Michaela Oeller","orcid":null,"position":1,"is_corresponding":false},{"id":1198558,"name":"Eva Rohde","orcid":"0000-0001-8692-886X","position":2,"is_corresponding":false},{"id":564787,"name":"Katharina Schallmoser","orcid":"0000-0002-7204-0058","position":3,"is_corresponding":false},{"id":564790,"name":"Dirk Strunk","orcid":"0000-0003-1810-867X","position":4,"is_corresponding":false},{"id":1689137,"name":"Sandra Laner-Plamberger","orcid":"0000-0002-1416-6023","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Heparin and Derivatives for Advanced Cell Therapies","abstract":"<jats:p>Heparin and its derivatives are saving thousands of human lives annually, by successfully preventing and treating thromboembolic events. Although the mode of action during anticoagulation is well studied, their influence on cell behavior is not fully understood as is the risk of bleeding and other side effects. New applications in regenerative medicine have evolved supporting production of cell-based therapeutics or as a substrate for creating functionalized matrices in biotechnology. The currently resurgent interest in heparins is related to the expected combined anti-inflammatory, anti-thrombotic and anti-viral action against COVID-19. Based on a concise summary of key biochemical and clinical data, this review summarizes the impact for manufacturing and application of cell therapeutics and highlights the need for discriminating the different heparins.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34769471","pmcid":null,"openalex_id":null,"authors":[],"funders":[{"funder_name":"European Commission","grant_id":"731377","title":"Multisystem Cell Therapy for Improvement of Urinary Continence"},{"funder_name":"European Commission","grant_id":"733006","title":"A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies"}],"total_grants":2,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"CC BY","oa_locations":[{"url":"https://doi.org/10.3390/ijms222112041","host_type":""},{"url":"https://www.mdpi.com/1422-0067/22/21/12041/pdf","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/34769471","host_type":""},{"url":"http://dx.doi.org/10.3390/ijms222112041","host_type":""},{"url":"https://dx.doi.org/10.3390/ijms222112041","host_type":""}],"fields_of_study":["0301 basic medicine","03 medical and health sciences"],"mesh_terms":[],"keywords":["Heparin","Cell- and Tissue-Based Therapy","Anticoagulants","Biocompatible Materials","Hemorrhage","Mesenchymal Stem Cells","Review","Regenerative Medicine","Thromboembolism","Cell Adhesion","Humans"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T02:22:37.532523Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}